Anbio Biotechnology (NASDAQ:NNNN) has filed to raise $8.8 million in an IPO of its Class A ordinary shares, according to an SEC F-1 registration statement. NNNN provides in vitro diagnostics products ...
Industry representatives have voiced their support for the Biotech Act, hoping it will improve financing and institutional support of IVD makers.
Zacks Investment Research on MSN
Tempus AI Enhances Cancer Research Tools With FDA-Cleared xR IVD
RNA sequencing provides a comprehensive view of biological information, offering deeper insights into disease mechanisms, including improved fusion detection. As a powerful tool in research and ...
Anbio Biotechnology is a medical device company. It is focused on developing and manufacturing a range of in-vitro diagnostic (IVD) products. The company was founded on July 27, 2021 and is ...
IVD Medical Holding Limited ( ($HK:1931) ) has shared an announcement. IVD Medical Holding Limited has confidentially submitted a draft ...
Anbio Biotechnology, a leader in in-vitro diagnostic technologies, announced its participation in three international exhibitions in May 2025: EuroMedLab in Brussels, AVA Conference in Sydney, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback